In contrast, in ctDNA sequencing MAPK alterations were more common in patients with ESR1 mutations overall (p = 0.001, Fig. 2b), and in HR + HER2- breast cancer (p = 0.02, Fig. 2b). This evidence concerns the gene ERBB2 and breast cancer.